$PSTI,...Pluristem surges on bullish research report
Thinly-traded micro cap Pluristem Therapeutics (NASDAQ:PSTI) is up 11% premarket on robust volume in apparent response to a bullish report from Acceleron equity research with a price target of $21. It estimates EPS of $0.40 in 2017 and $1.25 in 2018.
Acceleron believes the company will make significant progress this year in its clinical pipeline including shortening the time to market for its first product, PLX cells for critical limb ischemia, currently in Phase 2 in Europe. New Adaptive Licensing legislation in the European Union allows for limited commercialization of cell therapies after a successful Phase 2 study. Pluristem has yet to disclose a timeline for approval, however.
As with any investment opportunity, retail investors should complete their own thorough due diligence before considering taking action.
invest at your own risk, based on your own due diligence, at your own risk tolerance
